Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 2/20 | 0.58 |
| ▸ | PARP1 | P09874 | 1/20 | 0.58 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.55 |
| ▸ | GABRA1 | P14867 | 12/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 12/20 | 0.49 |
| ▸ | CNR2 | P34972 | 4/20 | 0.47 |
| ▸ | CNR1 | P21554 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10321982 | 0.77 | TNKS (0.52) | TNKSPARP1TNKS2GABRA1GABRB2 | |
| SCHEMBL8118653 | 0.77 | TNKS (0.79) | TNKSPARP1TNKS2GABRA1GABRB2 | |
| SCHEMBL17546624 | 0.76 | TNKS (0.68) | TNKSPARP1TNKS2GABRA1GABRB2 | |
| SCHEMBL29009100 | 0.74 | TNKS (0.65) | TNKSPARP1TNKS2GABRA1GABRB2 | |
| Ether SCHEMBL2462711 | 0.72 | KDM4E (0.48) | TNKSPARP1TNKS2GABRA1GABRB2 | |
| SCHEMBL2493537 | 0.71 | TNKS (0.63) | TNKSPARP1TNKS2GABRA1GABRB2 | |
| SCHEMBL24161890 | 0.71 | TNKS (1.00) | TNKSPARP1TNKS2GABRA1GABRB2 | |
| SCHEMBL8725419 | 0.71 | ALDH1A1 (0.48) | GABRA1GABRB2CNR2CNR1MEN1 | |
| SCHEMBL8731487 | 0.71 | ALDH1A1 (0.48) | GABRA1GABRB2CNR2CNR1MEN1 | |
| SCHEMBL11817910 | 0.71 | GABRA1 (0.52) | TNKSPARP1TNKS2GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017183864-A1 | COMPOSITION FOR NOROVIRUS CULTURE AND METHOD FOR NOROVIRUS CULTURE | 전남대학교산학협력단 | 2017-10-26 | — | — | WO | claimed |
| EP-2983473-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS Mountain Llc (US) | 2016-02-17 | — | — | EP | claimed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | claimed |
| WO-2014144130-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC (US) | 2014-09-18 | — | — | WO | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| WO-2017183864-A1 | COMPOSITION FOR NOROVIRUS CULTURE AND METHOD FOR NOROVIRUS CULTURE | 전남대학교산학협력단 | 2017-10-26 | — | — | WO | disclosed |
| EP-2983473-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS Mountain Llc (US) | 2016-02-17 | — | — | EP | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | disclosed |
| WO-2014144130-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| US-8486922-B2 | Composition | CHEN CHIEN-HUNG (TW) | 2013-07-16 | — | — | US | disclosed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | TNKS 1755/4885PARP1 3616/4885TNKS2 1714/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | TNKS 1755/4885PARP1 3616/4885TNKS2 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.